Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.

This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.

Condition or disease

Intervention/treatment

Phase

X-linked Retinoschisis

Biological: rAAV2tYF-CB-hRS1

Phase 1Phase 2

Detailed Description:

This will be a non-randomized, open label, Phase 1/2 dose escalation study.

Up to 27 participants will be enrolled. Each participant will receive the study agent by intravitreal injection in one eye on a single occasion. Enrollment will begin with the lowest dose and will proceed to higher doses only after review of safety data by a Data and Safety Monitoring Committee (DSMC). Participants in the dose escalation phase will be ≥ 18 years of age. After the maximum tolerated dose is identified individuals ≥ 6 years of age will be enrolled.

Safety will be measured by the number and proportion of participants experiencing adverse events and immune response to RS1. Efficacy will be measured by evaluation of changes in visual function and schisis cavity size.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

6 Years and older (Child, Adult, Senior)

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria include:

Retinal disease consistent with a diagnosis of XLRS and documented mutations in the RS1 gene

Male individual at least 18 years of age (dose escalation phase) or at least 6 years of age (maximum tolerated dose phase),

Able to perform tests of visual and retinal function,

Visual acuity specified for each group

Not treated with CAIs currently or within 3 months prior to study enrollment,

Have acceptable laboratory parameters.

Exclusion Criteria include:

Prior receipt of any AAV gene therapy product,

Pre-existing eye conditions that would preclude the planned intravitreal injection or interfere with interpretation of study endpoints or complications of vector administration.